Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.

Slides:



Advertisements
Similar presentations
Stenting: tips and tricks
Advertisements

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Five-year clinical follow-up of unprotected left main bifurcation lesion.
MSCT integration for complex bifurcation Alice Ohanessian MC Morice, T. Lefevre, Y.Louvard ICPS, Massy France Institut Cardiovasculaire Paris Sud.
Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute.
FFR et bifurcation. FFR et MB avant ATL MB SB ? 1.Intermediate stenoses (Pijls et al. New Engl J Med 1996) (Pijls et al. JACC 2010) 2.Post-myocardial.
A multicenter, randomized, prospective DKCRUSH-III study
Bifurcation Overview A comprehensive overview of Bifurcation disease, treatment options and techniques.
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Bifurcation Stenting: A primer
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
Evaluation of ReeKross balloon catheter in treating iliofemoral artery chronic total occlusions Xinwu Lu Vascular Center of Shanghai Jiaotong University.
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Lianglong Chen MD PhD FACC
Featuring Bifurcation Trans-Radial Approach Technical Issues Martial Hamon Caen, France Provisionnal T stenting With the Frontier stent Main Branch Balloon.
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Tryton Pivotal IDE-RCT Results Implications For Everyday Practice Integrating Dedicated Technology Antonio L. Bartorelli, FACC, FESC Centro Cardiologico.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Disclosure Statement of Financial Interest
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Open cervical approach for carotid artery stenting
The Endocross Enabler-P: First in-Human Results
Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,
INFRATIBIAL INTERVENTIONS Current Results with DES
Will we ever see a dedicated bifurcated DES in clinical practice?
Bifurcation Balloon & Stent Delivery System
Bifurcation PCI: Basic Techniques and Data from Clinical Trials
Nico H.J. Pijls, William F. Fearon, Peter Jüni, and Bernard De Bruyne
Updates From NOTION: The First All-Comer TAVR Trial
Abbott Vascular Bifurcation Program
Quantitative Flow Ratio (QFR)
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Bifurcation Management Update:
(DES)+BVS +DCB for long diffuse LAD disease
How to Handle a Complex Bifurcation Lesion
A Novel “Stent-On-A-Wire”Ultra Low Profile Stent Delivery System
Carotid Artery Stenting Predictors of procedural and clinical success
Strategy planning in coronary bifurcation stenting
Emerging FFR Non-Wire-based Technology
Crossing SFA-Popliteal Artery CTO’s
A Fixed Guidewire Stent Delivery System
SFA Access for TASC D lesions.
The Tryton Bifurcation Trial:
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
The XIENCE V EXCEED Study
Subintimal Tracking and Reentry for CTO STAR Method
OCT-Guided PCI What needs to be done to establish criteria?
The FDA’s View on CTO-PCI Devices
Erica Takai, PhD for Andrew Farb, M.D.
Catheter-Based Treatment of Coronary Artery Disease
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Translation Pathway for Coronary Stent Development- Clinical Endpoints
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
APPROACH TO CORONARY BIFURCATION LESIONS
Presentation transcript:

Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University of Copenhagen Denmark

Disclosure Statement of Financial Interest I, (Jens Flensted Lassen) DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

Disclosure Statement of Financial Interest ……. BUT !!! I, (Jens Flensted Lassen) am a Board member and one of the Directors of the European Bifurcation Club (EBC) and my view on bifurcation stenting is heavily influenced by the thoughts and consensus statements of EBC.

Treating coronary bifurcations Why is it difficult? True versus non-true bifurcations Small and Large SB Diameter difference between MB and SB MB tapering Angels between MB and SB 4-D movements Extension of disease in SB

EuroIntervention 2014;10: Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings

© 2015 EuroIntervention. All rights reserved. EuroIntervention 2015;11:V106-V110 Differences between the left main and other bifurcations

4-D movements

EuroIntervention 2014;10: Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings

Treating Bifurcation Lesions Why is it difficult? Anatomic Variation – Side Branch : Main Branch Diameter – Angle of Bifurcation Disease Burden: Wide Variation Difficult to Assess

Workhorse DES: Optimized for Straight Lesions Poorly Suited to of Bifurcation Lesions Wide Variety of Techniques Required Poorly Characterized/Inconsistently Performed: crush, culotte, reverse culotte, internal crush, reverse crush, T, provisional T, Y, extended Y, V, SKS, shotgun, Helqvist, sleeve, modified crush, Buchbinder, minicrush, mini crush, short back and sides, DK crush, flower

Predilate – side branch and/or main branch Safety wire P.O.T. Kiss/No Kiss Post Dilate – Non vs Semi Compliant – Sizing Many Techniques: Many Questions ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?

EuroIntervention 2015;11:V96-V98

Patient level meta analysis of BBC1 & NORDIC 1 Circ Cardiovasc interv. 2011;4:57-64

EuroIntervention 2014;10: Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings

"Life can only be understood backwards; but it must be lived forwards.“ Søren Kirkegaard ( Danish philosopher) The dilemma in the provisional side branch stenting in Bifurcation lesions

EBC Consensus: Side branch diameter and length can both be used visually as surrogates for volume of muscle at risk. Large side branches with ostial disease extending >5mm from the carina are likely to require two stents. Side branches whose access is particularly challenging should be secured by stenting once accessed.

Bifurcation Lesions: Defining The Need Coverage Radial Strength Addresses All – Angulation – SB-MB Diameter Differences – Disease Burden Ease-of-Use Tracking (Single Wire) Equipment (Operator’s Choice) – Guide Catheters (5 or 6 Fr) – Guidewires Compatibility: Workhorse stent (DES or BMS ) USER ISSUES CLINICAL REQUIREMENTS

Dedicated Bifurcation Stents: Difficult Design Problem: Many Failures

Historical Dedicated Devices Failed Clinically Not ‘easy to use’ Larger profile than workhorse stents Rotational orientation required Two wire tracking Poor Clinical Outcomes Lower Procedural Success than standard stenting Higher Event Rates than standard stenting

The Ideal Dedicated Device Easy to use and safe Simplify the procedure - Shorten procedural time, reduce X-ray exposure - reduce contrast media Allow continuously SB access (wire) Predictable successful ostial SB-stenting High rate of procedural success Optimal long terms results (restenosis & ST-rates, low) Abel to treat all kinds of bifurcations. Abel to be flexible during cardiac cycles

Tryton Tryton Pivotal Trials (RCT and Confirmatory): Landmark studies Improvement in clinical outcomes in large branches. Long-term results required. Simplified 2-stent technique New guidelines include incorporation of dedicated stents (Tryton).

Complex (1.1.1) Bifurcation Lesion Involving a Large Side Branch (LAD-D1) Baseline Tryton

- Dedicated devices should focus on: 1)Easy, safe and quick, treatment of the Left Main 2)Protection of a side branch the operator don´t want to loose ESC & EBC 2014 (15) Consensus

Conclusion – the way forward Evaluate dedicated devices in “significant” SB Dedicated devices already challenge 2-stent techniques – Ease of use (simplified technique) – Designed, tested, and approved for bifurcation Indications for dedicated devices – Large Side branches – Complex Disease – Left Main Dedicated devices may challenge provisional stenting - Ease of use (simplified technique)

Thank you for your attention "Life can only be understood backwards; but it must be lived forwards.“ Søren Kirkegaard ( Danish philosopher)